Role of antiangiogenic agents in the treatment of metastatic colorectal cancer

Cover Page

Cite item

Full Text

Abstract

This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage.

About the authors

M. V. Zabelin

Federal Medical and Biological Agency of Russia

Author for correspondence.
Email: maximzabelin@mail.ru
Russian Federation

S. S. Gordeev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
Russian Federation

L. O. Petrov

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
Russian Federation

A. A. Kostin

National Medical Radiology Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0792-6012
Russian Federation

S. E. Varlamova

State Research Center – Burnasyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia

Email: fake@neicon.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.